Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.
BACKGROUND All targeted therapies approved for ROS1-fusion-positive non-small cell lung cancer (NSCLC) are type I inhibitors. These TKIs may induce resistance amenable to type II inhibition. Cabozantinib is a type II ROS1/MET tyrosine kinase inhibitor with preclinical activity against on-target ROS1 resistance mutation...